Rachael Rettner, MyHealthNewsDaily Staff Writer
Warren
Buffett, chief executive of Berkshire Hathaway Inc. and the third-richest man
in the world, revealed yesterday (April 17) he has prostate cancer. Buffett is
one of about 240,000 men who will be diagnosed with prostate cancer in the
United States this year.
Here are
five things you should know about prostate cancer.
Disease of old age
Prostate
cancer is most common among men over age 65, and is rarely found in men under
age 40, according to the National Institutes of Health. It is the second most
common cancer in men, after skin cancer, according to the Centers for Disease
Control and Prevention.
Autopsy
studies show as many as 75 percent of men over age 85 had prostate cancer when
they died, though the disease was not necessarily lethal, according to the U.S.
Preventative Services Task Force.
Many
prostate cancers are slow growing and will not affect a man's health or life,
because men die from other causes before the cancer kills them, the task force
says.
Screening is
controversial
Doctors can
screen for prostate cancer using the prostate-specific antigen (PSA) blood
test, but its use in healthy men without symptoms remains controversial. Last
year, the task force recommended against routine prostate cancer screening in
healthy men, saying that for those ages 50 to 69, the benefit of screening was
small to none.
Studies on
the topic also have conflicting results. A recent study of 76,000 men ages 55
to 74 in the United States found men who
underwent yearly screening for prostate cancer were just as
likely to die from the disease as those who underwent screening only if their
doctor recommended it. On the other hand, a European study published last month
found prostate
cancer screening does save lives, but may need to be carried out for
more than 10 years to have a benefit.
The American
Cancer Society recommends men discuss with their doctor the
pros and cons of PSA screening to make a decision about whether testing is
right for them.
Overdiagnosis
a problem
A major
concern with PSA testing is that it finds cancers that would never have been
diagnosed otherwise, meaning the cancers would not have gone on to cause
significant health problems for patients. In the recent European study, about
half of cancers detected by PSA tests fell into this category.
Such
overdiagnosis is a problem because men may receive tests and treatment they do
not need. Side effects of prostate cancer treatment include erectile
dysfunction and loss of urinary control.
Monitoring
rather than treating
Currently,
about 10 percent of men diagnosed with prostate cancer delay treatment, while
the remaining 90 percent receive treatments such as surgery or radiation
therapy, according to the National Institutes of Health.
However,
about 40 percent of men diagnosed each year, or 100,000 men in the United
States, could delay treatment with a strategy called active
surveillance, according to a recent NIH panel. Under active
surveillance, patients with low-risk prostate cancer receive regular follow-up
testing and are treated only if the cancer becomes more aggressive.
Many experts
believe active surveillance is a way to reduce the harms of screening.
Reducing
risks
One way to
reduce prostate cancer risk is with diet. Studies show vegetarians have a lower
risk of prostate cancer than men who eat meat, according to the National
Institutes of Health. A nutrient called lycopene, found in tomatoes, has been
consistently linked with lower prostate cancer risk, according to the Mayo
Clinic. Evidence also suggests that vitamin D may lower men's risk of
developing a deadly form of prostate cancer.
Exercise to
maintain a healthy weight can also reduce your risk, the Mayo Clinic says.
Obesity has been shown to increase the
risk of aggressive prostate cancer.
No comments:
Post a Comment